Skip to content

Ketamine versus propofol for emergency intubation in critically ill adults – a multicentre observational study of hospital mortality and peri-intubation complications.

Protocol for a multicentre target-trial emulation comparing ketamine and propofol in critically ill adults undergoing emergency intubation.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12626000104358
Enrollment
400
Registered
2026-01-28
Start date
2025-08-05
Completion date
2026-01-01
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This retrospective cohort study compares ketamine- versus propofol-based induction for emergency intubation in critically ill adults. We will analyse Monash Health ICU data (2018-24) using causal inference methods. Primary outcome is hospital mortality; secondary outcome is a composite of haemodynamic collapse or severe hypoxaemia within 30 minutes. We hypothesise ketamine is associated with lower peri-intubation complications and improved survival.

Interventions

Brief description of the exposure: Ketamine given at the time of emergency endotracheal intubation as the principal sedative–hypnotic induction agent (rapid-sequence induction), with other co-induction medications (e.g., opioids, neuromuscular blockade) permitted. Cases where both ketamine and propofol are used as mixed induction (“ketofol”) are excluded from the primary analysis. What is involved for participants: This is a retrospective study using routinely collected, de-identified clinical

Brief description of the exposure: Ketamine given at the time of emergency endotracheal intubation as the principal sedative–hypnotic induction agent (rapid-sequence induction), with other co-induction medications (e.g., opioids, neuromuscular blockade) permitted. Cases where both ketamine and propofol are used as mixed induction (“ketofol”) are excluded from the primary analysis. What is involved for participants: This is a retrospective study using routinely collected, de-identified clinical data (EMR, intubation records and clinical information systems). There are no questionnaires, no additional samples, and no participant contact. A waiver of consent applies due to retrospective de-identified data. Duration of observation: Time zero is the timestamp of induction drug administration. Participants are observed for (i) 0–30 minutes post-intubation for peri-intubation physiological endpoints, and (ii) from induction until death, hospital discharge, or 28 days, whichever occurs first, for the primary outcome. Study period : Jan 2019-Jan 2024

Sponsors

Monash Health - ICU Research Team - Rafael von Hellmann
Lead SponsorIndividual

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• Adults = greater than or equal to 18 years • Emergency endotracheal intubation (ED, ward or ICU) • Non-elective, non-OR • Admitted to Monash ICU afterwards

Exclusion criteria

Elective Intubations Not admitted to Monash Health ICU's

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 7, 2026